Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy
FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC
EMA Validates MAA for Frontline Nivolumab/Ipilimumab for MSI-H/dMMR mCRC
Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology
Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection
Retrospective Data Show Association Between HER2 Expression and Survival Outcomes in mCRC
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
